A Phase I Pharmacokinetics and Safety Study of Two Dapivirine Intravaginal Gels

HIV Infections Clinical Trial

Official title:

A Double-Blind, Randomized, Placebo-Controlled Phase I Study to Compare the Pharmacokinetics of Intravaginal Dapivirine Gel 4750, 0.05%, 2.5g and Dapivirine Gel 4789, 0.05%, 2.5g Formulations and to Assess the Safety as Compared to the Intravaginal HEC-Based Universal Placebo Gel, 2.5g in Healthy HIV-Negative Women.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00613249
• Other study ID #: IPM 012
• Status: Completed
• Phase: Phase 1
• First received: January 31, 2008
• Last updated: March 26, 2009
• Start date: November 2007
• Est. completion date: March 2008

Study information

• Verified date: March 2009
• Source: International Partnership for Microbicides, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium: Federal Agency for Medicinal Products and Health Products
• Study type: Interventional

Clinical Trial Summary

IPM 012 is a double-blind, randomized, placebo-controlled phase I study conducted at one research center in Belgium among 36 healthy, HIV-negative women of 18-40 years of age, randomized in a 1:1:1 ratio to assess plasma, vaginal fluid and vaginal tissue levels and the pharmacokinetics of dapivirine when applying either Dapivirine Gel 4750, 0.05%, 2.5g or Dapivirine Gel 4789, 0.05%, 2.5g intravaginally for 11 days (1 day followed by a 3 day washout period and then 10 consecutive days); and to assess the safety of these gels as compared to the intravaginal HEC-based universal placebo gel.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: March 2008
• Est. primary completion date: March 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Women between 18 and 40 years of age, inclusive

• Willing and able to give written informed consent

• Available for all visits and consent to follow all procedures

• Healthy, based on medical history, vital signs, physical examination, urinalysis, laboratory evaluations for genital infections and laboratory evaluations for hematology, liver and renal function

• HIV-negative as determined by a HIV-1 ELISA test at enrollment

• Willing to abstain from sexual activity for the duration of the study

• On stable oral contraceptive regimen for 2 months prior to enrollment and willing to continue

• Upon pelvic/speculum examination, the cervix and vagina appear normal

• Willing to refrain from the use of vaginal products from 14 days prior to enrollment and for the duration of the study

Exclusion Criteria:

• History of alcoholism, drug abuse, psychosis, antagonistic personality, poor motivation or other emotional or intellectual problems that are likely to invalidate the informed consent process or adversely impact adherence with protocol requirements

• History of sensitivity/allergy to any component of the study product or to latex

• Currently pregnant or breast-feeing, or within 3 months of last pregnancy outcome

• Currently or within one month of participating in any other clinical research study

• History or current diagnosis and/or treatment for a STD within the last three months prior to enrollment

• Current vulvar, vaginal or cervical symptoms/abnormalities as determined by pelvic/speculum exam or colposcopy that could influence the study results

• History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding or urethral obstruction within the last 3 months

• Current non-iatrogenic pelvic/colposcopic exam findings involving deep epithelial disruption

• Smoking more than 10 cigarettes a day

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

• HIV Infections

Intervention

Drug:
• Dapivirine Gel 4750, 0.05%, 2.5g
intravaginal gel, dosed daily
• Dapivirine Gel 4789, 0.05%, 2.5g
intravaginal gel, dosed daily
• HEC-based Placebo Gel
intravaginal gel, dosed daily

Locations

Country	Name	City	State
Belgium	SGS Life Science Services Research Unit Stuivenberg	Antwerp

Sponsors (1)

Lead Sponsor	Collaborator
International Partnership for Microbicides, Inc.

Country where clinical trial is conducted

Belgium, 

References & Publications (1)

Nel A, Smythe S, Habibi S, Romano J. 2009. Comparison of Safety and PK of Two Formulations of Dapivirine Vaginal Gel in Healthy, HIV-Negative Women [abstract]. 16th Conference on Retroviruses and Opportunistic Infections; 2009 Feb 8-11; Montreal. Availabl

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serial dapivirine concentrations in plasma, vaginal fluid and cervical-vaginal tissue samples		11 days	No
Primary	Self-reported genital symptoms, pelvic/colposcopic exam findings, laboratory evaluations and adverse events/serious adverse events		14 days	No